Loading clinical trials...
Loading clinical trials...
A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)
Conditions
Interventions
ZD6474, Vandetanib
ZD6474, Vandetanib
+2 more
Locations
15
Italy
Research Site
Brescia, BS, Italy
Research Site
Florence, FI, Italy
Research Site
Genova, GE, Italy
Research Site
Milan, Mi, Italy
Research Site
Palermo, PA, Italy
Research Site
Aviano, PN, Italy
Start Date
October 1, 2008
Primary Completion Date
September 1, 2012
Completion Date
September 1, 2012
Last Updated
October 10, 2016
NCT05489211
NCT04900818
NCT07146646
NCT07398339
NCT06428409
NCT07282262
Lead Sponsor
Genzyme, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions